Drug Profile
Pidilizumab - CureTech
Alternative Names: CT-011; MDV 9300Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator CureTech
- Developer American Cancer Society; Beth Israel Deaconess Medical Center; CureTech; Georgia Regents University; Hadassah Medical Organization; Northwestern University; The Ohio State University Comprehensive Cancer Center; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Bispecific antibodies
- Mechanism of Action Delta like 1 protein inhibitors; Programmed cell death-1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Glioma
Highest Development Phases
- Phase II Acute myeloid leukaemia; Colorectal cancer; Follicular lymphoma; Malignant melanoma; Multiple myeloma; Pancreatic cancer; Prostate cancer; Renal cell carcinoma
- Phase I/II Glioma; Hepatitis C; Liver cancer
- No development reported Diffuse large B cell lymphoma
Most Recent Events
- 16 Apr 2021 No development reported - Phase-II for Diffuse large B cell lymphoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
- 16 Apr 2021 No development reported - Phase-II for Diffuse large B cell lymphoma in India (IV)
- 16 Apr 2021 No development reported - Phase-II for Diffuse large B cell lymphoma in Israel (IV)